Sysmex Europe
Sysmex Europe
Other Sites
Menu

Please select your country. This will keep you up to date with your country-specific information.

OncoBEAM in colorectal cancer

  • Quick. Whenever. Just blood.
  • Reliable detection of RAS and BRAF mutations
  • Highly sensitive liquid biopsy (MAF 0.02%)

Documents

All
  • All
  • Brochure
Documents

OncoBEAM in colorectal cancer

Why test for RAS and BRAF mutation in colorectal cancer (CRC)?

Clinical guidelines recommend expanded RAS testing to select metastasised CRC (mCRC) patients eligible for anti-EGFR therapy.1,2 For all patients with stage IV metastatic CRC at diagnosis, BRAF mutation analysis is also recommended as an indicator of poor prognosis.2 The potential clinical utility of BRAF inhibitors in combination with anti-EGFR therapy is currently being investigated in clinical trials.

To test for these clinically actionable mutations, minimally invasive liquid biopsy has become a valuable tool. It delivers real-time and unbiased information supporting treatment decisions and monitoring of the patient’s response to treatment or the emergence of resistance.3

The Sysmex Inostics’ OncoBEAM RAS CRC IVD kit provides unparalleled sensitivity and thereby ensures reliable detection of RAS mutations from plasma samples, also at very low mutant allele fractions (MAFs). This provides guidance for physicians regarding therapy selection. Using the OncoBEAM RAS CRC IVD kit for monitoring RAS mutations during anti-EGFR therapy may provide early insight into predicting clinical outcomes in mCRC patients as well.3.6

The clinical value of the OncoBEAM RAS CRC IVD kit has been demonstrated in various studies and is applied worldwide in our centres of excellence for helping physicians in selecting the right therapy at the right time for the right patients.

Available products

OncoBEAM RAS CRC (IVD)
Detection of 34 RAS mutations – 16 mutations in KRAS codons 12, 13, 59, 61, 117, 146 and 18 mutations in NRAS codons 12, 13, 59, 61, 117, 146 – in cell-free DNA extracted from 3 mL of plasma. The test is intended to aid clinicians in determining the potential benefit of anti-epidermal growth factor receptor (EGFR) therapy for colorectal cancer patients.

OncoBEAM BRAF (RUO*)
Detection of BRAF V600E mutation in cell-free DNA extracted from 3 mL of plasma.

*For research use only. Any in vitro diagnostics purpose has not been established by the manufacturer.

OncoBEAM in lung cancer

OncoBEAM liquid biopsy for
mutation detection

Oncology

The OncoBEAM advantage

The OncoBEAM advantage

1. High concordance with tissue
OncoBEAM™ RAS CRC Kit demonstrated an overall percent agreement of 93.3 % with tissue (4)

2. Safe and convenient
Minimally invasive, low risk

3. Accurate information
Blood sample evaluation represents patient's current mutational status; information of tumour dynamics in real time (5)

4. No selection bias
Evaluate primary tumour and metastases from one sample

5. Ability to monitor
Allows multiple measurements to assess drug response and resistance (3,6)

Video: OncoBEAM Technology

Video: OncoBEAM Technology

Video: The oncologist’s experience

Video: The oncologist’s experience

Video: The patient’s experience with OncoBEAM

Video: The patient’s experience with OncoBEAM

References

References

  1. NCCN Clinical Practise Guidelines in Oncology: Colon Cancer. National Comprehensive Cancer Network. V2, 2017.
  2. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–1422.
  3. Toledo R et al. (2017): Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget. 8(21):35289 – 35300.
  4. OncoBEAM™ RAS CRC Kit Instructions for Use, OBMRASIVD.
  5. Tabernero J et al. (2015): Analysis of Circulating DNA and Protein Biomarkers to Predict the Clinical Activity of Regorafenib and Assess Prognosis in Patients with Metastatic Colorectal Cancer: A Retrospective, Exploratory Analysis of the CORRECT Trial. The Lancet Oncology 16(8):937 – 948.
  6. Vidal et al., (2017): Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 20171;28(6):1325-1332.
Sysmex Inostics Technologies & Services

Sysmex Inostics Technologies & Services

Want to know more about Sysmex Inostics offers?

Website: www.sysmex-inostics.com

Contact

Sysmex Europe GmbH

+49 (40) 527 26 0
+49 (40) 527 26 100
info@sysmex-europe.com
Bornbarch 1
22848 Norderstedt
Germany

Create Pdf
Watch Penny’s story
Watch video
Watch video
Enjoy our Media Centre
All
  • All
  • Documents
  • Podcast
  • Images
  • Videos
See our collection
Find your job